Avantax Advisory Services Inc. Has $421,000 Position in Harrow, Inc. (NASDAQ:HROW)

Avantax Advisory Services Inc. boosted its holdings in Harrow, Inc. (NASDAQ:HROW) by 11.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 12,534 shares of the company’s stock after acquiring an additional 1,273 shares during the period. Avantax Advisory Services Inc.’s holdings in Harrow were worth $421,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Harrow by 443.1% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after buying an additional 194,480 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Harrow by 195.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,629 shares of the company’s stock valued at $11,313,000 after purchasing an additional 166,602 shares in the last quarter. Braidwell LP grew its holdings in shares of Harrow by 47.9% during the 3rd quarter. Braidwell LP now owns 439,638 shares of the company’s stock valued at $19,766,000 after purchasing an additional 142,450 shares during the last quarter. BNP Paribas Financial Markets increased its position in Harrow by 3,015.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 79,974 shares of the company’s stock worth $3,596,000 after purchasing an additional 77,407 shares in the last quarter. Finally, Penserra Capital Management LLC bought a new position in Harrow in the 3rd quarter valued at approximately $1,986,000. 72.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

HROW has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $57.00 target price on shares of Harrow in a research report on Tuesday, March 18th. B. Riley cut their price objective on Harrow from $73.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, December 4th.

Harrow Stock Up 1.1 %

NASDAQ:HROW opened at $28.41 on Monday. Harrow, Inc. has a one year low of $9.86 and a one year high of $59.23. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The company has a market cap of $1.01 billion, a PE ratio of -30.22 and a beta of 0.69. The firm’s 50 day simple moving average is $29.51 and its 200 day simple moving average is $38.38.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.